Get the Stockscreener App
0.00
100.00%
-0.10
After Hours:
.02
0.02
+
Telesis Bio Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$0.10
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
$30.00M
Net Income/Loss:
$-38.17M
P/E Ratio:
0.00
EPS:
-1.3
Net Cash Flow:
$-35.49M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-69.27%
1Y Performance:
-85.40%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.1956
Telesis Bio Inc Stock (TBIO) Company Profile
Compare TBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBIO
Telesis Bio Inc
|
0.00 | 0 | 30.00M | -38.17M | -35.49M | -1.30 |
|
ABT
Abbott Laboratories
|
131.87 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.11 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
390.88 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.02 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.88 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Telesis Bio Inc Stock (TBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-18-21 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-18-21 | Downgrade | Truist | Buy → Hold |
| Oct-05-20 | Initiated | Goldman | Buy |
| Jul-07-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-06-20 | Initiated | William Blair | Outperform |
| Jun-26-20 | Initiated | SunTrust | Buy |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jun-18-19 | Initiated | ROTH Capital | Buy |
| Dec-24-18 | Initiated | H.C. Wainwright | Buy |
| Jul-23-18 | Initiated | Citigroup | Buy |
| Jul-23-18 | Initiated | Evercore ISI | Outperform |
| Jul-23-18 | Initiated | Leerink Partners | Outperform |
View All
Telesis Bio Inc Stock (TBIO) Latest News
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Global mRNA Synthesis and Manufacturing Market to Increase at a Steady Growth Rate of ~4% by 2032 | DelveInsight - GlobeNewswire
Telesis Bio Inks Regeneron Deal - San Diego Business Journal
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results - Insider Monkey
Regeneron to deploy Telesis Bio’s Gibson SOLA at R&D facilities - Yahoo Finance
Regeneron partners with Telesis Bio for swift on-site gene synthesis - World Pharmaceutical Frontiers
Telesis Bio and Regeneron Partner on Gene Synthesis - Technology Networks
Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&D Efficiency - Insider Monkey
Regeneron (REGN) Adopts Telesis Bio's Gene Synthesis Platform | - GuruFocus
Regeneron Pharmaceuticals (NasdaqGS:REGN) Adopts Innovative Technology for Faster Drug Discovery - Yahoo Finance
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis - BioSpace
TBIOTRANSLATE BIO, INC. Latest Stock News & Market Updates - Stock Titan
Driving Synthetic Biology Forward Through Adoption of Technology Enabling Rapid DNA and mRNA Synthesis - MedCity News
What is going on with the stock tbio - AInvest
Telesis Bio (NASDAQ:TBIO) Stock Price Up 28.9% – Here’s Why - American Banking and Market News
Telesis Bio (NASDAQ:TBIO) Trading Up 28.9% – Still a Buy? - Defense World
Telesis Bio Bullish on Future After Whirlwind Year - San Diego Business Journal
TELESIS BIO INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
FT ranking: The Americas’ Fastest-Growing Companies 2025 - Financial Times
Telesis Bio (NASDAQ:TBIO) Trading Down 23.1% – Here’s Why - Defense World
$21M Investment Powers Telesis Bio's Game-Changing Overnight DNA Synthesis Technology - StockTitan
Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis - Yahoo Finance
Telesis Bio (NASDAQ:TBIO) Trading 27.3% Higher – Should You Buy? - Defense World
Financial Contrast: Telesis Bio (NASDAQ:TBIO) and Prenetics Global (NASDAQ:PRE) - Defense World
Nuclera appoints William J. Kullback as Non-Executive Director - Cambridge Network
Carver Bancorp Leads 3 Noteworthy US Penny Stocks - simplywall.st
Telesis Bio Inc. Faces Financial Challenges Amidst Revenue Decline - TipRanks
Telesis Bio's Chief Legal Officer To Leave Post This Week - Law360
One new option listing and ten option delistings on October 21st - TipRanks
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62% - MSN
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket - MSN
Telesis Bio Stock Skyrockets after Beckman Coulter Partnership - timothysykes.com
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis - Yahoo Finance
Is Telesis Bio Inc. on the Brink of a Major Breakthrough? - timothysykes.com
Codex DNA stock plunges to 52-week low of $1.65 - Investing.com
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market | TBIO Stock News - Stock Titan
Telesis Bio completes sale of subsidiary EtonBio - Investing.com
Enzymatic DNA Synthesis Market Size | Industry Report 2033 - Grand View Research
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results - Yahoo Finance
DNA Synthesis Market Size, Share | Growth Report [2025-2032] - Fortune Business Insights
Telesis Bio Reports First Quarter 2024 Financial Results - Yahoo Finance
Telesis Bio Announces Reverse Stock Split - Yahoo Finance
Telesis Bio appoints new CEO as founder steps down - Investing.com
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results - Koreabizwire
Press Release Service: Enzymatic DNA Synthesis Market to Surge to US$2.11 Billion by 2028 Driven by Advances in Synthetic Biology and Genetic Engineering TechnologiesResearchAndMarkets.com - CRISPR Medicine News
New research finds that despite the stereotypes, women actually negotiate their salaries more than men - Fortune
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023, Business Wires News - AsiaOne
Enzymatic DNA Synthesis Market 2022: Explore Top Factors that Will Boost the Global Market by 2028 - openPR.com
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit - Technology Networks
Telesis Bio to Present at Jefferies Healthcare Conference 2023 - Koreabizwire
Sidley Represents Northpond Ventures in Its PIPE Investment in Telesis Bio Inc. - Sidley Austin LLP
Telesis Bio Inc Stock (TBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.54%
Cap:
|
Volume (24h):